Condition: Hepatic Cancer · Hepatic Resection · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
The presence of certain mutations in HCC, such as TERT and TP53, have a suspected or proven prognostic role in resected patients, but lack a morphological or immunophenotypic counterpart, which would allow us to define which tumours are rationally candidate for molecular biology analysis. The identification of a histological and immunohistochemical algorithm to determine which HCCs to take to NGS for prognostic purposes will save time and economic costs in the laboratory by rationalising available resources. In the future, the application of the immunohistochemical and molecular algorithm on biopsy could allow better prognosis and predictivity even before surgery/therapy.
This description comes directly from the study's public registry record.
Francecso Vasuri, MD · 0512143761 · francesco.vasuri2@unibo.it
Deborah Malvi, MD · 0512143761 · deborah.malvi@aosp.bo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06718153